ARID1A mutations are particularly prevalent in gynecologic cancers (found in 10–60% of ovarian and endometrioid carcinoma cases) [42] and pre-malignant gynecological lesions, especially of endometrioid origin [43]. This evidence concerns the gene ARID1A and female reproductive organ cancer.